OpenLobby.EU
Explore

A. Menarini Industrie Farmaceutiche Riunite s.r.l.

A. Menarini s.r.l.

Menarini is an Italian pharmaceutical company focusing on research, innovation, and international healthcare.

Lobbying Activity

Meeting with Mariateresa Vivaldini (Member of the European Parliament, Shadow rapporteur for opinion)

21 Jan 2026 · medicines

Meeting with Ondřej Knotek (Member of the European Parliament)

21 Jan 2026 · Health Policy

Meeting with Nicolás González Casares (Member of the European Parliament)

21 Jan 2026 · Biotechnology, Critical medicines, pharmaceutical policy

Meeting with Aurelijus Veryga (Member of the European Parliament)

15 Jan 2026 · EU Policy Tools to Safeguard Access to Critical Medicines

Menarini Group Urges More Flexible EU Pharmaceutical State Aid

6 Oct 2025
Topic — A public consultation on revising the General Block Exemption Regulation for state aid.
Message — The group requests agile aid rules for AI-driven research and strategic pharmaceutical production. They seek the inclusion of reshoring activities to strengthen European health resilience. They also propose removing complex counterfactual scenarios and rigid regional investment constraints.123
Why — Simplified rules would reduce administrative costs and enable more large-scale industrial investments.45
Impact — Environmental protections might be undermined by the group's push for flexible sustainability criteria.67
Read full response

Meeting with András Tivadar Kulja (Member of the European Parliament)

17 Sept 2025 · Cardiovascular diseases, oncology, pain/inflammation, asthma

Meeting with Tiemo Wölken (Member of the European Parliament, Shadow rapporteur) and Pro Generika e.V.

16 Sept 2025 · Critical Medicines Act

Menarini urges EU to prioritize innovative cardiovascular therapies

15 Sept 2025
Topic — The initiative seeks to reduce cardiovascular disease burden through better prevention and treatment.
Message — Menarini urges the effective implementation of medical guidelines and removal of obstacles to innovative therapies. They recommend supporting combination therapy and routine health measurements to reach cardiovascular risk targets. The group also advocates for a research mission supporting the entire drug development cycle.123
Why — Policy shifts favoring new drugs would increase their market reach and reduce development hurdles.45
Impact — National health budgets may face higher costs if current restrictions on expensive treatments are removed.6
Read full response

Meeting with Alessandra Moretti (Member of the European Parliament)

4 Sept 2025 · Critical Medicine Act

Meeting with Tiemo Wölken (Member of the European Parliament, Shadow rapporteur) and European Federation of Pharmaceutical Industries and Associations and

17 Jul 2025 · Critical Medicines Act

Meeting with Mohammed Chahim (Member of the European Parliament, Shadow rapporteur for opinion)

11 Jul 2025 · Critical Medicines Act (follow up)

Meeting with Mohammed Chahim (Member of the European Parliament, Shadow rapporteur for opinion) and European Federation of Pharmaceutical Industries and Associations and

25 Jun 2025 · Roundtable Critical Medicines Act

Meeting with Francesco Torselli (Member of the European Parliament, Shadow rapporteur for opinion)

21 May 2025 · Incontro conoscitivo

Meeting with Tomislav Sokol (Member of the European Parliament, Rapporteur) and BGP Products Operations GmbH – a Viatris Company

13 May 2025 · Health policy

Meeting with András Tivadar Kulja (Member of the European Parliament)

24 Apr 2025 · Critical medicines act

Meeting with Nicolás González Casares (Member of the European Parliament)

8 Apr 2025 · Health

Meeting with Maurice Whelan (Head of Unit Joint Research Centre), Tobias Wiesenthal (Head of Unit Joint Research Centre) and

4 Apr 2025 · Scientific roundtable discussion between the European Commission’s Joint Research Centre and the pharmaceutical industry on the topic of leveraging health data and data sciences for innovation

Meeting with Aurelijus Veryga (Member of the European Parliament)

2 Apr 2025 · Discussion on the Critical Medicines Act and its role in improving medicine availability and supporting EU-based manufacturing

Meeting with Giulia Del Brenna (Head of Unit Internal Market, Industry, Entrepreneurship and SMEs)

18 Mar 2025 · Menarini, a €3 billion revenue pharmaceutical manufacturer, mostly active in the generic medicines domain, wanted to discuss the recently adopted Commission proposal for a Critical Medicines Act (CMA), and provide some first reactions.

Meeting with Susanna Ceccardi (Member of the European Parliament)

21 Feb 2024 · Meeting with Menarini Group

Meeting with Tomislav Sokol (Member of the European Parliament, Shadow rapporteur)

23 Jan 2024 · Pharmaceutical legislation

Meeting with Tiemo Wölken (Member of the European Parliament, Rapporteur) and AbbVie

18 Dec 2023 · Revision of Pharmaceutical Package (staff level)

Meeting with Nicola Danti (Member of the European Parliament) and Associazione delle Imprese del farmaco

7 Nov 2023 · Posizione su revisione pacchetto farmaceutico

Meeting with Sirpa Pietikäinen (Member of the European Parliament)

3 Nov 2023 · Pharmaceutical Package, AMR

Meeting with Patrizia Toia (Member of the European Parliament)

19 Apr 2023 · Pharmaceutical Strategy